



COMPANY OVERVIEW

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies for the treatment of cancer. The Company's investigational technology, ImmunoPulse®, is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, OncoSec's lead program, ImmunoPulse® IL-12, demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. ImmunoPulse® IL-12 is currently in Phase II development for several indications, including metastatic melanoma and triple negative breast cancer. In addition to ImmunoPulse® IL-12, the Company is also seeking to identify and develop new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

RECENT NEWS

OncoSec Presents Update on PISCES/KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial in Combination with Merck's KEYTRUDA® for Metastatic Melanoma at the ASCO 2018 Annual Meeting

Jun 4 2018, 8:00 AM EDT

OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

May 8 2018, 7:30 AM EDT

STOCK OVERVIEW

Symbol	ONCS	Exchange	Nasdaq
Market Cap	75.38m	Last Price	\$1.44
52-Week Range	\$0.88 - \$2.95	Fiscal Year End	December 31

MANAGEMENT TEAM

Daniel J. O'Connor

Chief Executive Officer, President and Director

Richard B. Slansky

Chief Financial Officer

Christopher G. Twitty, Ph.D.

Chief Scientific Officer

Sharron Gargosky, PhD

Chief Clinical and Regulatory Officer

ONCOSEC MEDICAL INCORPORATED

3565 General Atomics Ct.
San Diego, CA 92121
US

INVESTOR RELATIONS

T: 855-ONCOSEC (855-662-6732)
investors@oncosec.com

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.